This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Sharps Compliance Reports $5.4 Million In Revenue In Third Quarter Fiscal 2013

Stocks in this article: SMED

  • Strong growth in targeted Retail, Professional and Assisted Living markets
  • 22% growth in billings through inside and online sales channel in the third quarter; Reached record quarterly level of $0.8 million
  • Balance sheet remains solid with cash of $16.1 million, working capital of $17.4 million

HOUSTON, May 1, 2013 (GLOBE NEWSWIRE) -- Sharps Compliance Corp. (Nasdaq:SMED) ("Sharps" or the "Company"), a leading full-service provider of solutions for the cost-effective management of medical waste, used healthcare materials and unused dispensed medications, today reported financial results for the third quarter of fiscal year 2013 ended March 31, 2013.

Revenue in the third quarter of fiscal 2013 was $5.4 million. Growth in key targeted markets helped to offset the $0.2 million decrease associated with the maintenance portion of a U.S. Government contract with the Division of Strategic National Stockpile of the Centers for Disease Control that was terminated on January 31, 2012. Comparable core market revenue for the third quarter of fiscal 2012 was $5.1 million.

Customer billings, the Company's measure for performance and progress of the business, decreased $0.2 million, or 3.9%, when compared with the prior year period, reflecting the $0.2 million impact from the termination of the maintenance portion of the U.S. government contract. Excluding that impact, core customer billings were unchanged year-over-year at $5.2 million in the third quarter of fiscal 2013. Solid growth in billings to the Retail, Professional and Assisted Living markets were offset by lower billings to the Pharmaceutical market, which were softer due to the timing of orders from three new Patient Support Programs in the prior year. On a sequential basis, core customer billings decreased $0.3 million, or 5.1%, compared with $5.5 million in the trailing second quarter which had higher billings to the Pharmaceutical market. This is an indication of the variability quarter-to-quarter in orders from this market. (See Reconciliation of Customer Billings to Revenue in the supplemental table included at the end of this release.)

David P. Tusa, President and CEO of Sharps Compliance, commented, "We believe our concerted efforts to be recognized as a preferred provider of comprehensive medical waste management services and to better educate the market place regarding our solutions are beginning to deliver results. Our repositioning has greatly improved the quality of our pipeline and we are beginning to realize growth in markets that value an alternative provider of comprehensive medical waste management services throughout North America. We believe our timing is very good as our prospective customers are looking for cost savings during these uncertain times in healthcare. In addition, we see our strong relationships with retail and pharmaceutical manufacturer customers and our growing Professional market customer base as a testament to the value of our medical waste management solutions including our regulatory compliance offerings."

1 of 7

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,762.93 +85.03 0.51%
S&P 500 1,957.08 +6.26 0.32%
NASDAQ 4,467.2030 +14.4110 0.32%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs